Head-To-Head Analysis: Cyclo Therapeutics (NASDAQ:CYTH) & Quantum Genomics Société Anonyme (OTCMKTS:QNNTF)

Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) and Cyclo Therapeutics (NASDAQ:CYTH) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends and valuation.

Volatility and Risk

Quantum Genomics Société Anonyme has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500. Comparatively, Cyclo Therapeutics has a beta of -0.49, meaning that its share price is 149% less volatile than the S&P 500.

Earnings and Valuation

This table compares Quantum Genomics Société Anonyme and Cyclo Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Genomics Société Anonyme	N/A	N/A	N/A	N/A	N/A
Cyclo Therapeutics	$1.08 million	20.94	-$20.06 million	($0.90)	-0.87

Quantum Genomics Société Anonyme has higher earnings, but lower revenue than Cyclo Therapeutics.

Insider & Institutional Ownership

68.6% of Cyclo Therapeutics shares are owned by institutional investors. 29.8% of Cyclo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Quantum Genomics Société Anonyme and Cyclo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Quantum Genomics Société Anonyme	N/A	N/A	N/A
Cyclo Therapeutics	-2,847.19%	N/A	-307.16%

Analyst Recommendations

This is a breakdown of recent ratings for Quantum Genomics Société Anonyme and Cyclo Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Genomics Société Anonyme	0	0	0	0	0.00
Cyclo Therapeutics	0	2	1	0	2.33

Cyclo Therapeutics has a consensus target price of $0.95, indicating a potential upside of 20.87%. Given Cyclo Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Cyclo Therapeutics is more favorable than Quantum Genomics Société Anonyme.

Summary

Cyclo Therapeutics beats Quantum Genomics Société Anonyme on 6 of the 9 factors compared between the two stocks.

About Quantum Genomics Société Anonyme

Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. The company develops its drugs based on brain inhibition mechanism of Aminopeptidase A: BAPAI, a triple-action therapeutic platform primarily to treat high blood pressure and heart failure. It is developing firibastat, a treatment for high blood pressure, and in combination with others anti-hypertensive drugs. The company also is involved in the development of drugs for the treatment of high blood pressure as monotherapy and the prevention, as well as treatment of heart failure. Quantum Genomics Société Anonyme was incorporated in 2005 and is based in Paris, France.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.